FDA halts use of Evusheld due to low effectiveness

Friday, 27. January 2023 06:40

The US Food and Drug Administration (FDA) withdrew AstraZeneca's COVID-19 antibody treatment from the market due to the medicine not being effective against 93% of coronavirus subvariants currently registered in the United States.

"Today's action to limit the use of Evusheld prevents exposing patients to possible side effects of Evusheld such as allergic reactions, which can be potentially serious, at a time when fewer than 10% of circulating variants in the US causing infection are susceptible to the product," the FDA's statement noted.

Evusheld is used as a preventive measure before getting infected with COVID-19, with more than a million doses distributed across the US since December 2021. There's no replacement for the drug at this moment.

Related Links: AstraZeneca plc
Baha Breaking News (BBN) / ND